Founded in 2019 as a spin-off of the University of Zurich, Somagenetix is at the forefront of gene therapy innovation, focused on curing phagocyte disorders with a one-in-a-lifetime treatment. The company’s proprietary platform technology overcomes the limitations of traditional gene therapies by ensuring unprecedented safety and cellular specificity while providing long-term therapeutic effectiveness. Somagenetix has built a best-in-class gene therapy platform, harnessing the potential of the latest generation of lentivirus for several dozen known genetic disorders.

Somagenetix’s lead therapy, SGX-001, is on track to enter human clinical trials in 2026, with the goal of curing Chronic Granulomatous Disease (CGD) — a serious immune deficiency with no lasting treatment options — driven by a commitment to extend its breakthroughs to other inherited diseases and neurodegenerative disorders.